Imprimis, Advanced Dosage sign license agreement for proprietary compounded ophthalmic formulations
Imprimis Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of proprietary compounded drug formulations, today announced that it has entered into a license agreement with Advanced Dosage Forms, Inc. to expand Imprimis' proprietary ophthalmic injectable and combination topical compounded formulations into Canada. Under the agreement, the licensee has the rights to formulate, market and sell these formulations across Canada.